648 related articles for article (PubMed ID: 7621565)
1. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
White D; Leigh A; Wilson C; Donaldson A; Franks S
Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
[TBL] [Abstract][Full Text] [Related]
2. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome.
Gilling-Smith C; Story H; Rogers V; Franks S
Clin Endocrinol (Oxf); 1997 Jul; 47(1):93-9. PubMed ID: 9302378
[TBL] [Abstract][Full Text] [Related]
3. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
Kuhl H; Jung C; Taubert HD
Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
[TBL] [Abstract][Full Text] [Related]
4. Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma.
Fulghesu AM; Angioni S; Belosi C; Apa R; Selvaggi L; Ciampelli M; Iuculano A; Melis GB; Lanzone A
Clin Endocrinol (Oxf); 2006 Sep; 65(3):396-401. PubMed ID: 16918963
[TBL] [Abstract][Full Text] [Related]
5. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
6. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist.
Chang RJ; Laufer LR; Meldrum DR; DeFazio J; Lu JK; Vale WW; Rivier JE; Judd HL
J Clin Endocrinol Metab; 1983 May; 56(5):897-903. PubMed ID: 6403570
[TBL] [Abstract][Full Text] [Related]
7. 17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome P450c17alpha dysregulation.
Sahin Y; Keleştimur F
Hum Reprod; 1997 May; 12(5):910-3. PubMed ID: 9194638
[TBL] [Abstract][Full Text] [Related]
8. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
[TBL] [Abstract][Full Text] [Related]
9. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
10. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries.
Gilling-Smith C; Willis DS; Beard RW; Franks S
J Clin Endocrinol Metab; 1994 Oct; 79(4):1158-65. PubMed ID: 7962289
[TBL] [Abstract][Full Text] [Related]
11. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
Kaltsas GA; Korbonits M; Isidori AM; Webb JA; Trainer PJ; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2000 Oct; 53(4):493-500. PubMed ID: 11012575
[TBL] [Abstract][Full Text] [Related]
12. Ovarian suppression in polycystic ovarian disease during 6 month administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
Faure N; Lemay A
Clin Endocrinol (Oxf); 1987 Dec; 27(6):703-13. PubMed ID: 3138052
[TBL] [Abstract][Full Text] [Related]
13. Pituitary-ovarian relationships in polycystic ovary syndrome.
Baird DT; Corker CS; Davidson DW; Hunter WM; Michie EA; Van Look PF
J Clin Endocrinol Metab; 1977 Oct; 45(4):798-801. PubMed ID: 334789
[TBL] [Abstract][Full Text] [Related]
14. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.
Cheung AP; Lu JK; Chang RJ
Hum Reprod; 1997 Jun; 12(6):1156-64. PubMed ID: 9221993
[TBL] [Abstract][Full Text] [Related]
15. Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome.
Pierre A; Peigné M; Grynberg M; Arouche N; Taieb J; Hesters L; Gonzalès J; Picard JY; Dewailly D; Fanchin R; Catteau-Jonard S; di Clemente N
Hum Reprod; 2013 Mar; 28(3):762-9. PubMed ID: 23321213
[TBL] [Abstract][Full Text] [Related]
16. 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome.
Sahin Y; Keleştimur F
Clin Endocrinol (Oxf); 1993 Aug; 39(2):151-5. PubMed ID: 8396511
[TBL] [Abstract][Full Text] [Related]
17. LH pulsatility and response to a single s.c. injection of buserelin in polycystic ovary syndrome.
Prelević GM; Würzburger MI; Balint-Peric L
Gynecol Endocrinol; 1990 Mar; 4(1):1-13. PubMed ID: 2110712
[TBL] [Abstract][Full Text] [Related]
18. Modified dexamethasone and gonadotropin-releasing hormone agonist (Dx-GnRHa) test in the evaluation of androgen source(s) in hirsute women.
Bidzińska B; Tworowska U; Demissie M; Milewicz A
Przegl Lek; 2000; 57(7-8):393-6. PubMed ID: 11109312
[TBL] [Abstract][Full Text] [Related]
19. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.
Steingold K; De Ziegler D; Cedars M; Meldrum DR; Lu JK; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1987 Oct; 65(4):773-8. PubMed ID: 3116031
[TBL] [Abstract][Full Text] [Related]
20. Source localization of androgen excess in adolescent girls.
Ibáñez L; Potau N; Zampolli M; Prat N; Gussinyé M; Saenger P; Vicens-Calvet E; Carrascosa A
J Clin Endocrinol Metab; 1994 Dec; 79(6):1778-84. PubMed ID: 7989484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
